Page 1

☐ evommune Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights - Company to announce EVO756 atopic dermatitis ( AD ) Phase 2b top - line data in September 2026 -EVO756 migraine prophylaxis Phase 2b dose - ranging trial recently initiated with top - line data in 2027 - EVO301 full Phase 2a positive data set supporting planned Phase 2b trial in AD to be presented at upcoming medical conference - Strong balance sheet , with cash through 2028 to deliver multiple key data readouts across the pipeline PALO ALTO , Calif . & NEW YORK , August 6 , 2026 Evommune , Inc. ( NYSE EVMN ) ( “ Evommune ” or the " Company " ) , a clinical - stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases , today announced financial results for the second quarter ended June 30 , 202 , and provided a business update . " There are still no first - line oral options for patients suffering with AD that combine lesion control , itch relief and tolerability . That gap is where we believe EVO75 can make a difference , as it targets neurogenic mast cell biology and non - histaminergic itch . We are e cited to deliver top - line Phase 2b data ne t month . We also believe the underlying biology and market opportunity are especially compelling in migraine prophyla is̟ and that EVO75 could define the ne t wave of preventative treatments . We are very e cited to have the Phase 2b trial now underway and e pect top - line data ne t year , " said Luis Peña , President and Chief E ecutive Officer at Evommune . “ Taken together , these milestones reflect the continued e ecution of our mission - driven approach to developing transformative therapies for people living with immune - mediated diseases . " Recent Business Highlights and Upcoming Milestones EVO756 - Oral MRGPR Antagonist Program Potential first and best - in - class , potent and highly selective small molecule antagonist of Mas - related G protein- coupled receptor X2 ( MRGPRX2 ) , a receptor predominantly found on both mast cells and peripheral sensory neurons . This dual e pression allows MRGPRX2 to uniquely modulate the neurogenic inflammation feedback loop between nerves and immune cells that drive chronic inflammation .